 |
|
Moonlighting enzyme linked to neurodegenerative disease
April 25, 2007Friedreich's ataxia is one of those diseases few have heard of unless you know someone with the condition. For that individual -- usually a child or teenager -- it is devastating. Symptoms are mild at first: muscle weakness in the arms and legs, vision impairment and slurred speech, but eventually the symptoms progress and most patients become wheelchair-bound and succumb to heart failure later in life. There is no cure at this time, but Mayo Clinic researchers have identified mutations in an enzyme that may contribute to the disease.
"Children and teens want to be on top of the world and having a disease like this is devastating for them and their families in so many different respects," says Grazia Isaya, M.D., Ph.D., senior author of the study and a basic scientist at Mayo Clinic who specializes in Friedreich's ataxia. "Their cognitive functions are not impaired so they understand exactly what is happening to them."
Friedreich's ataxia is an inherited neurodegenerative disease of children and teens and is considered an orphan disease by the National Institutes of Health because of its rarity -- affecting one in 40,000. It is associated with a deficiency of frataxin, a protein that balances iron in mitochondria, which are the structures that convert nutrients into energy for cells. A new Mayo Clinic study published in the April issue of the Proceedings of the National Academy of Sciences (PNAS) shows that mutations in a moonlighting enzyme, dihydrolipoamide dehydrogenase (DLD), are responsible for decreasing the enzyme's primary role as a metabolizer, while increasing its role in breaking down frataxin, its second job.
Moonlighting proteins and enzymes are molecules that perform two or more different functions. These proteins are thought to have evolved because they can provide cells with significant advantages, namely, the ability to increase the spectrum of metabolic activities without increasing the number of protein-coding genes, and the ability to coordinate different metabolic pathways.
Mutations in DLD have been linked to severe metabolic disorders in humans, but it wasn't known that DLD was a moonlighting enzyme with two jobs: regulating metabolism and breaking down proteins.
The PNAS study describes how Mayo investigators identified DLD's role in reducing the amount of frataxin that is produced.
"These findings reveal a previously unrecognized mechanism by which certain DLD mutations can simultaneously induce the loss of a primary metabolic activity and the gain of a moonlighting proteolytic (breaking down enzymes) activity. The latter could contribute to the metabolic derangement associated with DLD deficiency and represent a target for therapies of this condition," the authors write.
Like all proteins, frataxin is continuously synthesized, and it carries out its function before it breaks down. Some proteins degrade more rapidly than others, but frataxin degrades at a much more rapid pace than other proteins. "We observed this degradation years ago and in doing so, we decided to go after the enzyme responsible for the degradation thinking it probably might play an important role in the regulation of frataxin and could represent a target therapy for Friedreich's ataxia," says Dr. Isaya.
The severity of Friedreich's ataxia is proportional to the decrease in the levels of frataxin: the lower the frataxin, the more severe the disease. "Yet, this correlation does not completely explain the clinical variability because even within the same family we may see individuals with different phenotypes -- one more severe than the other," Dr. Isaya says.
In Friedreich's ataxia, clinicians have long hypothesized the existence of gene modifiers -- genes that can influence the outcome of other gene mutations. "We believe that the enzyme we've identified is most likely a modifier of Friedreich's ataxia because mutations in that gene could increase or decrease the levels of frataxin in patients," she says.
Identifying and confirming the role of this moonlighting enzyme could aid in the development of new therapies for patients with Friedreich's ataxia. In addition, further study could confirm the presence of mutations in the enzyme that could explain, in part, differing clinical phenotypes among patients.
Dr. Isaya says: "Understanding protein function is central to being able to provide individualized clinical care to patients who may, for example, carry different mutations of this enzyme and express different clinical phenotypes."
Mayo Clinic
Moonlighting proteins and enzymes are molecules that perform two or more different functions. These proteins are thought to have evolved because they can provide cells with significant advantages, namely, the ability to increase the spectrum of metabolic activities without increasing the number of protein-coding genes, and the ability to coordinate different metabolic pathways.
Mutations in DLD have been linked to severe metabolic disorders in humans, but it wasn't known that DLD was a moonlighting enzyme with two jobs: regulating metabolism and breaking down proteins.
The PNAS study describes how Mayo investigators identified DLD's role in reducing the amount of frataxin that is produced.
"These findings reveal a previously unrecognized mechanism by which certain DLD mutations can simultaneously induce the loss of a primary metabolic activity and the gain of a moonlighting proteolytic (breaking down enzymes) activity. The latter could contribute to the metabolic derangement associated with DLD deficiency and represent a target for therapies of this condition," the authors write.
Like all proteins, frataxin is continuously synthesized, and it carries out its function before it breaks down. Some proteins degrade more rapidly than others, but frataxin degrades at a much more rapid pace than other proteins. "We observed this degradation years ago and in doing so, we decided to go after the enzyme responsible for the degradation thinking it probably might play an important role in the regulation of frataxin and could represent a target therapy for Friedreich's ataxia," says Dr. Isaya.
The severity of Friedreich's ataxia is proportional to the decrease in the levels of frataxin: the lower the frataxin, the more severe the disease. "Yet, this correlation does not completely explain the clinical variability because even within the same family we may see individuals with different phenotypes -- one more severe than the other," Dr. Isaya says.
In Friedreich's ataxia, clinicians have long hypothesized the existence of gene modifiers -- genes that can influence the outcome of other gene mutations. "We believe that the enzyme we've identified is most likely a modifier of Friedreich's ataxia because mutations in that gene could increase or decrease the levels of frataxin in patients," she says.
Identifying and confirming the role of this moonlighting enzyme could aid in the development of new therapies for patients with Friedreich's ataxia. In addition, further study could confirm the presence of mutations in the enzyme that could explain, in part, differing clinical phenotypes among patients.
Dr. Isaya says: "Understanding protein function is central to being able to provide individualized clinical care to patients who may, for example, carry different mutations of this enzyme and express different clinical phenotypes."
Mayo Clinic
Neurodegenerative Disease Current Events and Neurodegenerative Disease News RSSNovel mouse gene reduces major pathologies associated with Alzheimer's disease
A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD).
Mouse gene suppresses Alzheimer's plaques and tangles
Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau.
Widely used cholesterol-lowering drug may prevent progression
Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease.
Member of NFL Hall of Fame diagnosed with degenerative brain disease
The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a recently deceased member of the NFL Hall of Fame suffered from the degenerative brain disease Chronic Traumatic Encephalopathy (CTE) when he died, becoming the 10th former NFL player diagnosed with the disease.
First former college football player diagnosed with CTE
The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a deceased former college football player who died at age 42 was already suffering from the degenerative brain disease, Chronic Traumatic Encephalopathy (CTE).
Natural compounds, chemotherapeutic drugs may become partners in cancer therapy
Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy.
August 10, 2009 New Class of Compounds Discovered for Potential Alzheimer's Disease Drug, Penn Study Finds
A new class of molecules capable of blocking the formation of specific protein clumps that are believed to contribute to the dementia of Alzheimer's disease (AD) patients has been discovered by researchers at the University of Pennsylvania School of Medicine.
Caffeine reverses memory impairment in Alzheimer's mice
Coffee drinkers may have another reason to pour that extra cup. When aged mice bred to develop symptoms of Alzheimer's disease were given caffeine - the equivalent of five cups of coffee a day - their memory impairment was reversed.
Huntington's disease deciphered
Researchers at the University of Illinois at Chicago College of Medicine have discovered how the mutated huntingtin gene acts on the nervous system to create the devastation of Huntington's disease.
What separates dangerous blood vessel plaques from benign ones
Researchers say they have evidence to explain what separates your average blood vessel plaque from those that are at high risk for triggering the development of dangerous-even fatal-blood clots.
More Neurodegenerative Disease Current Events and Neurodegenerative Disease News Articles
 |
Oxidative Stress in Cancer, AIDS, and Neurodegenerative Diseases (Oxidative Stress and Disease, 1) by Montagnier (Author) Presents basic, chemical, biological, and medical studies of free radicals on different targets and the consequences of their reactivity-covering the chemistry and biochemistry of free radicals, free radicals as second messengers that group the activation of transcription factors and enzymes, the importance of the antioxidant system in cell metabolism regulation, and the role of free radicals and antioxidants in disease management. Written by over 200 international authorities, the book offers incisive discussions on the significance of oxidant-antioxidant balance and cytotoxicity of free radicals when produced in excess by several sources, specifically radiation hydrogen peroxide as a stimulant of transcription factor NFkB leading to cell response against oxidative stress ... |
 |
Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics by M. Flint Beal (Author), Anthony E. Lang (Author), Albert C. Ludolph (Author) Neurodegenerative diseases are major contributors to disability and disease, with Alzheimer's and Parkinson's diseases the most prevalent. This major reference reviews the rapidly advancing knowledge of pathogenesis and treatment of neurodegenerative diseases in the context of a comprehensive survey of each disease and its clinical features. The editors and contributors are among the leading experts in the field internationally. Covering basic science, diagnostic tools and therapeutic approaches, the book focuses on all aspects of neurodegenerative disease, including the normal aging process. The dementias, prion diseases, Parkinson's disease and atypical parkinsonisms, neurodegenerative ataxias, motor neuron diseases, degenerative diseases with chorea, iron and copper disorders, and... |
 |
Neurodegenerative Diseases and Metal Ions: Metal Ions in Life Sciences by Astrid Sigel (Editor), Helmut Sigel (Editor), Roland K. O. Sigel (Editor) About the Series... Metal Ions in Life Sciences links coordination chemistry and biochemistry in their widest sense and thus increases our understanding of the relationship between the chemistry of metals and life processes. The series reflects the interdisciplinary nature of Biological Inorganic Chemistry and coordinates the efforts of scientists in fields like biochemistry, inorganic chemistry, coordination chemistry, molecular and structural biology, enzymology, environmental chemistry, physiology, toxicology, biophysics, pharmacy, and medicine. Consequently, the volumes are an essential source for researchers active in these and related fields as well as teachers preparing courses, e.g., in Bioinorganic Chemistry. About this Book... Volume 1, devoted... |
 |
Fatal Attractions: Protein Aggregates in Neurodegenerative Disorders (Research and Perspectives in Alzheimer's Disease) by V.M.-Y. Lee (Editor), J.Q. Trojanowski (Editor), L. Buee (Editor), Y. Christen (Editor) In this volume are contributions based on a meeting arranged by the WHO and the Fondation IPSEN. The scientists focus on neurodegenerative disorders like Alzheimer's Disease, Chromosome 17-Linked Dementia, Parkinson's Disease and disorders with tauopathies. |
 |
So Much So Fast Starring: Stephen Heywood, Jamie Heywood Directed By: Steven Ascher;Jeanne Jordan What would you do if you were 29 and found you may only have a few years to live? So Much So Fast is about the remarkable events set in motion when Stephen Heywood discovers he has ALS (Lou Gehrig's disease) and his brother Jamie becomes obsessed with finding a cure. |
 |
Glutamine Repeats and Neurodegenerative Diseases: Molecular Aspects by Peter S. Harper (Editor), Max Perutz (Editor) (The Royal Society) Univ. of Wales, Cardiff, UK. Molecular biology text focuses on the discovery of a common pathogenic basis for a group of genetically inherited disorders, including Huntington's Disease. Discusses how these diseases share certain molecular similarities, what causes neurodegeneration to begin, and other important discoveries. For researchers and clinicians. |
 |
Molecular Mechanisms of Neurodegenerative Diseases (Contemporary Clinical Neuroscience) by Marie-Francoise Chesselet (Editor) Univ. of California, Los Angeles. First volume in this series. Synthesizes novel ideas and concepts emerging to create a fresh understanding of neurodegenerative disorders, details mechanistic similarities in Alzheimer's, Parkinson's, and related diseases. DNLM: Neurodegenerative Diseases--genetics. |
 |
Heat Shock Proteins and the Brain: Implications for Neurodegenerative Diseases and Neuroprotection (Heat Shock Proteins) by Alexzander A.A. Asea (Author), Alexzander A.A. Asea (Editor), Ian R. Brown (Editor) With the prevalence of neurodegenerative diseases on the rise as average life expectancy increases, the hunt for effective treatments and preventive measures for these disorders is a pressing challenge. Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis have been termed 'protein misfolding disorders' that are characterized by the neural accumulation of protein aggregates. Manipulation of the cellular stress response involving the induction of heat shock proteins offers a therapeutic strategy to counter conformational changes in neural proteins that trigger pathogenic cascades resulting in neurodegenerative diseases. Heat shock proteins are protein repair agents that provide a line of defense against misfolded,... |
|
ADULTS WITH NEURODEGENERATIVE DISEASES: Occupational Therapy Practice Guidelines (Aota Practice Guidelines) by Susan Forwell (Author) | |
 |
Neurodegenerative Diseases: From Molecular Concepts to Therapeutic Targets by Rommy Von Bernhardi (Editor), Nibaldo C. Inestrosa (Editor) This book discusses in detail the different hypothesis and experimental evidence regarding the neurobiological mechanisms involved in neurodegenerative pathology, with an emphasis in Alzheimer's and Parkinson's disease. Since there are many hypotheses for neurodegenerative diseases, there is a real need for a comprehensive view, allowing for integration of the different views for the pathogenic mechanisms of the disease. |
| © 2009 BrightSurf.com |